Cas9 News and Research

RSS

Researchers discover new regions of non-coding DNA that may lead to cancer growth

In an unprecedented pan-cancer analysis of whole genomes, researchers at the Ontario Institute for Cancer Research have discovered new regions of non-coding DNA that, when altered, may lead to cancer growth and progression.

17 Jan 2020

Genetically engineered mosquitoes halt Dengue spread

A new study published in the journal PLOS Pathogens in January 2020 reports the development of mosquitoes that have been genetically modified to resist infection by several types of the dengue virus. This is the first time ever that all types of the virus have been targeted by the engineering of the mosquito DNA. Covering all virus types is essential to achieve proper disease control.

16 Jan 2020

ERS Genomics signs licensing agreement with Daiichi Sankyo

ERS Genomics today announced the signing of a license agreement with Daiichi Sankyo, a global pharmaceutical company with corporate origins in Japan.

14 Jan 2020

Horizon Discovery to offer novel base editing technology for clinical research

Horizon Discovery today announced that it will provide access to a novel base editing technology licensed from Rutgers for exclusive use in therapeutic, diagnostic and services applications.

From Revvity 14 Jan 2020

ERS Genomics and New England Biolabs sign agreement to commercialize CRISPR/Cas9 tools, reagents

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with New England Biolabs, a global leader in the discovery and production of enzymes for molecular biology applications, granting NEB rights to sell CRISPR/Cas9 tools and reagents.

From New England Biolabs 9 Jan 2020

Study shows potential new approach to treating two common subtypes of lymphoma

A study at The University of Texas MD Anderson Cancer Center demonstrated a potential new approach to treating two of the most common subtypes of lymphoma through manipulation of molecular programs controlled by the cAMP-response element binding protein.

8 Jan 2020

The first clinical trials of CRISPR gene editing have shown promising results

Results of clinical trials testing CRISPR suggest that treating diseases with the gene-editing tool may be on the horizon.

7 Jan 2020

Promega and MilliporeSigma sign license agreement to expand the potential of CRISPR

Promega announce license agreement with MilliporeSigma, a leader in genome editing, to access MilliporeSigma’s foundational CRISPR genome-editing technology.

From Promega Corporation 2 Jan 2020

Advancement in reconstitution of the blood system from human pluripotent stem cells

The reconstitution of the blood system in humans holds great therapeutic potential to treat many disorders, like blood cancers, sickle-cell anemia and others.

31 Dec 2019

Inserting end-modified DNA fragments with CRISPR-Cas9 yields highest efficiency

University of Illinois researchers achieved the highest reported rates of inserting genes into human cells with the CRISPR-Cas9 gene-editing system, a necessary step for harnessing CRISPR for clinical gene-therapy applications.

23 Dec 2019

Research shows how the hepatitis D virus copies itself

A team of researchers has discovered how one crucial step occurs in the lifecycle of the hepatitis D virus (HDV), which causes the widespread and hard to treat liver inflammation called hepatitis D. The study, which was published recently in the Journal of Virology, could help develop antiviral therapy to control this disease.

22 Dec 2019

Study uncovers a previously unknown subtype of muscle stem cells

Scientists have discovered a new subtype of muscle stem cells. These cells have the ability to build and regenerate new muscles, making them interesting targets for the development of gene therapies.

21 Dec 2019

Combined datasets can expedite the discovery and development of new cancer drugs

A comprehensive map of genes necessary for cancer survival is one step closer, following the validation of the two largest CRISPR-Cas9 genetic screens in 725 cancer models, across 25 different cancer types.

20 Dec 2019

First images of new gene editing complex which could upgrade CRISPR

Nobel Prize-winning technique used to capture images of a new gene-editing tool that could improve CRISPR-based tools.

19 Dec 2019

Study provides genomic insights into life history tradeoffs in butterflies

Have you ever wandered through your garden or a meadow on a summer day and wondered why and how butterflies exhibit such beautiful and diverse colors? Scientists have, especially when thinking about butterflies in the genus Colias. In most Colias butterflies, all males and most females are an orange or yellow color, but some females are white.

18 Dec 2019

A new function identified for glycine receptors during embryonic development

Glycine receptors are one of the most widely distributed inhibitory receptors in the central nervous system and have important roles in a variety of physiological processes.

18 Dec 2019

Tackling antibiotic resistance head-on with CRISPR

With modern advances in genetic engineering occurring almost every day, the latest discovery concerns antibiotic resistance. Using the powerful gene editor CRISPR, scientists reported the development of a gene-drive system that is 100 times as efficient as other current systems at inactivating a specific bacterial gene responsible for making the bacterium antibiotic-resistant and which is present as multiple copies within the same bacterial cell.

16 Dec 2019

New gene technology shows 100-fold efficiency in targeting antibiotic-resistant bacteria

Taking advantage of powerful advances in CRISPR gene editing, scientists at the University of California San Diego have set their sights on one of society's most formidable threats to human health.

16 Dec 2019

Neuroscientists develop new method for uniquely targeted gene therapy

Neuroscientists at Lund University in Sweden have developed a new technology that engineers the shell of a virus to deliver gene therapy to the exact cell type in the body that needs to be treated. The researchers believe that the new technology can be likened to dramatically accelerating evolution from millions of years to weeks.

13 Dec 2019

Horizon Discovery adds predesigned synthetic single guide RNA to its product range

Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, today announced the addition of predesigned synthetic single guide RNA (sgRNA) to its product range.

From Revvity 13 Dec 2019